Roche's Genentech defends supply shift for top cancer drugs

Roche's Genentech defends supply shift for top cancer drugs

Nov 24 (Reuters) – Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will

9
Like
Save

Comments

Write a comment

*